Biocon Entered into an Out-Licensing Agreement with Yoshindo to Commercialize bUstekinumab and bDenosumab in the Japan
- Biocon Biologics to receive an up front license fee along with an additional fee upon achievement of development milestones over the next few years
- Yoshindo to get exclusive commercialization right in Japan for bUstekinumab and bDenosumab which was developed and manufactured by Biocon Biologics. The clinical trials for these two assets initiated in 2022, and include both P-I & III trials along with robust pre-clinical CMC packages
- Ustekinumab, a biosimilar referencing Stelara is a mAb & is indicated to treat multiple autoimmune conditions, incl. psoriasis, CD, UC, PsO, and PsA. Denosumab, a biosimilar referencing Prolia is a mAb & is used for the treatment of osteoporosis
Ref: Biocon | Image: Biocon
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.